Heidelberg

Asher Bio Appoints Andrea Pirzkall, M.D., as Chief Medical Officer

Retrieved on: 
Monday, June 13, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Immunotherapy, Bevacizumab, BeiGene, Head, Research, Genentech, Atezolizumab, University Hospital Heidelberg, LinkedIn, UCSF, Radiation therapy, Drug, Medicine, IND, Multimedia, Therapy, University, Autoimmunity, Patient, Antioch University (San Francisco), Infection, Heidelberg, German Cancer Aid, Tislelizumab, Lung cancer, Industry, Neurosurgery, Third Rock Ventures, German Cancer Research Center, Radiation, Cancer, Pharmaceutical industry, Vaccine, Radiology

Asher Biotherapeutics, Inc. (Asher Bio) , a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the appointment of Andrea Pirzkall, M.D., as its first Chief Medical Officer.

Key Points: 
  • Asher Biotherapeutics, Inc. (Asher Bio) , a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the appointment of Andrea Pirzkall, M.D., as its first Chief Medical Officer.
  • View the full release here: https://www.businesswire.com/news/home/20220613005157/en/
    Asher Bio CMO Andrea Pirzkall MD (Photo: Business Wire)
    We are delighted to welcome Andrea to the Asher Bio team at this pivotal time as we transition to a clinical-stage company.
  • Andrea is an ideal fit to our team as we continue to advance our pipeline, said Craig Gibbs, Ph.D., Chief Executive Officer of Asher Bio.
  • For more information, please visit www.asherbio.com and follow Asher Bio on Twitter @AsherBio and on LinkedIn .

DGAP-News: Heidelberger Druckmaschinen AG: HEIDELBERG successfully closes fiscal year 2021/22 with after-tax profit – highest order backlog in 10 years

Retrieved on: 
Friday, May 6, 2022
United Kingdom, COVID-19, COVID 19, Investment, Mission statement, EBITDA, Twitter, Tax, Annual report, COVID, Environment, Industry, Board of directors, Heidelberg, Federal Executive Boards, Income, Efficiency, Sale, Climate, CEO, Growth, Recycling, Life insurance, Cryptocurrency

Demand picked up across almost all products and in all regions, with investments in new presses being the main driver.

Key Points: 
  • Demand picked up across almost all products and in all regions, with investments in new presses being the main driver.
  • As of March 31, 2022, the order backlog stood at around 900 million, the highest level in more than 10 years (previous year: 636 million).
  • "The high order backlog resulting from the noticeable market recovery in the past fiscal year provides a good foundation for sales in the new fiscal year.
  • The company will publish its annual financial statements and annual report for fiscal year 2021/22 on June 9, 2022.

Xpressdocs Unveils State-of-the-Art Headquarters

Retrieved on: 
Thursday, January 13, 2022
Xerox, Technology, Fortune 500, Growth, Printing, Solution, Heidelberg, Automation, View, Goal, Culture, Marketing, Coffee, Multimedia, HP, Premedia, HIPPA, Organization, Warehouse, Renewable energy, Online shopping

FORT WORTH, Texas, Jan. 13, 2022 /PRNewswire/ -- As Xpressdocs begins its 21st year in business, the company is pleased to officially introduce its new headquarters, a thoughtfully designed and constructed 245,000 square-foot facility.

Key Points: 
  • FORT WORTH, Texas, Jan. 13, 2022 /PRNewswire/ -- As Xpressdocs begins its 21st year in business, the company is pleased to officially introduce its new headquarters, a thoughtfully designed and constructed 245,000 square-foot facility.
  • "Our investment in a new office space is really an investment in our people," comments Xpressdocs COO Darrin Rayner.
  • "Our culture at Xpressdocs is strong, and we're happy to support the further development of our team in our new, improved space."
  • Xpressdocs is a proud partner to organizations that span the spectrum of growth phases, from start-ups to established Fortune 500 brands.

Affimed to Host Virtual Investor Call Today to Discuss Treatment of CD30-positive Lymphoma Patients with Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13

Retrieved on: 
Thursday, December 9, 2021
CFGB-FM, Forward-looking statement, Research, GLOBE, Review, SEC, Biotechnology, Global Monitoring Plan, Growth, NHL, Human, Safety, Cytokine release syndrome, Neurotoxicity, Cyclophosphamide, EST, NK, Patient, Industry, MD Anderson Cancer Center, Affimer, IST, Cancer, Macrophage, Graft-versus-host disease, FDG-PET, Maintenance, CRS, COVID-19, University, ORR, Hodgkin lymphoma, Clinical trial, IRR, Haematopoietic system, REDIRECT, Cell, Webcast, Pharmaceutical industry, Medical device, Vaccine

Three patients were treated with 1106, three patients with 1107 and 13 patients with 1108 AFM13-pre-complexed cbNK cells per kg body weight.

Key Points: 
  • Three patients were treated with 1106, three patients with 1107 and 13 patients with 1108 AFM13-pre-complexed cbNK cells per kg body weight.
  • In this cohort, 100% of patients responded after the first cycle of treatment with five CRs (38.5%) and seven PRs (61.5%).
  • AFM13 is a first-in-class innate cell engager (ICE) that uniquely activates the innate immune system to destroy CD30-positive hematologic tumors.
  • The ROCK platform predictably generates customized innate cell engager (ICE) molecules, which use patients immune cells to destroy tumor cells.

Affimed Initiates Patient Recruitment for a Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Roche’s Anti-PD-L1 Checkpoint Inhibitor Atezolizumab

Retrieved on: 
Wednesday, December 8, 2021
U.S. Securities and Exchange Commission, Forward-looking statement, Institute of Cancer Research, Population, GLOBE, Immunotherapy, CMO, Biotechnology, Pharmacokinetics, Royal Marsden Hospital, Disease, Security (finance), Â, Safety, Liver, NK, Patient, Lung, Affimer, Cancer, Large-cell lung carcinoma, CR, Adult, ORR, EGFR, NSCLC, Biology, The Institute, Pharmaceutical industry, Vaccine

By combining AFM24 with an immune checkpoint inhibitor, we aim to activate both the innate and the adaptive immune system to improve patient outcomes.

Key Points: 
  • By combining AFM24 with an immune checkpoint inhibitor, we aim to activate both the innate and the adaptive immune system to improve patient outcomes.
  • The first part is a dose escalation phase, aiming to determine the maximum tolerated dose/recommended phase 2 dose of AFM24 in combination with atezolizumab.
  • All patients have failed 1 prior line of treatment before receiving the combination of AFM24 and atezolizumab.
  • The ROCK platform predictably generates customized innate cell engager (ICE) molecules, which use patients immune cells to destroy tumor cells.

HP Indigo Accelerates Industry 4.0 Solutions Across Industry Segments and Digital Product Portfolio

Retrieved on: 
Thursday, December 2, 2021
HP, Algorithm, Automation, Robinsonia fogra, Heidelberg, Printing, API, Technology, Industry, General manager, PALO, Tanjungpinang, MIS, PSP, HP Indigo Division, NYSE, Compliance, Machine learning, Workflow, Hewlett-Packard, Solution, JDF, VP, Fourth Industrial Revolution, HP Inc., K, GLOBE, Mark (given name), Efficiency, Color, Visage SDK, QA, Growth, Featherbed Alley Printshop, HPQ, Certification, Warehouse, 3D printing, Online shopping, Electric motor

PALO ALTO, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- HP Inc. today unveiled new ways for print service providers to grow their digital-based business and put Industry 4.0 into practice by enabling better automated tools to enhance connectivity, productivity, and support customer growth as print service providers move to capture online business.

Key Points: 
  • Announcing enhanced integration with Heidelberg Prinect to seamlessly drive jobs to HP Indigo digital presses without intervention or adjustments.
  • Industry 4.0 practices are allowing HP Indigo print service providers to deliver thousands of digital print jobs every day.
  • On top of the already-supported Idealliance G7 color certification, PrintOS Color Beat now also automates Fogra color certification for new-generation HP Indigo commercial and labels-and-packaging presses including the HP indigo 100K, HP Indigo 15K, HP Indigo 12000 VP, HP Indigo 25K and HP Indigo 35K.
  • Automatic Alert Agent 2.0 for HP Indigo Series 4 digital presses (HP Indigo 12000 and 15K).

Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 for CD30-positive Lymphomas

Retrieved on: 
Monday, November 22, 2021
Patient, Review, Safety, MD Anderson Cancer Center, Cell, University, Affimer, Industry, Forward-looking statement, AACR, Cancer, Cyclophosphamide, Clinical trial, SEC, Human, NK, Graft-versus-host disease, COVID-19, Cytokine release syndrome, CRS, EST, Research, GLOBE, FDG-PET, Biotechnology, CFGB-FM, Global Monitoring Plan, Macrophage, Webcast, PRS, Hodgkin lymphoma, Division, Department, Growth, REDIRECT, Vaccine, Pharmaceutical industry

Eleven of twelve patients treated at the recommended phase 2 dose level of 108 cbNK cells per kg had Hodgkin Lymphoma.

Key Points: 
  • Eleven of twelve patients treated at the recommended phase 2 dose level of 108 cbNK cells per kg had Hodgkin Lymphoma.
  • AFM13 is a first-in-class innate cell engager (ICE) that uniquely activates the innate immune system to destroy CD30-positive hematologic tumors.
  • AFM13 induces specific and selective killing of CD30-positive tumor cells, leveraging the power of the innate immune system by engaging and activating natural killer (NK) cells and macrophages.
  • The ROCK platform predictably generates customized innate cell engager (ICE) molecules, which use patients immune cells to destroy tumor cells.

Affimed Shares Preclinical Data on Mechanism of Action of two Innate Cell Engagers at the 36th SITC Meeting, Demonstrating their Potential to Induce Antibody Dependent Cellular Phagocytosis and Serial Killing

Retrieved on: 
Friday, November 12, 2021
2D, SITC, Cancer, Macrophage, Industry, Neoplasm, Clinical trial, Disease, 3D, Society, Trial of the century, Growth, NK, CSO, EGFR, COVID-19, CD16, Forward-looking statement, Karolinska Institute, REDIRECT, Biotechnology, GLOBE, ADCP, SEC, PDX, Immunotherapy, Poster, Cell, Patient, M1, Pharmaceutical industry, Vaccine, Medical imaging

Showing serial killing for AFM13- and AFM24-engaged NK cells in single cell resolution is impressive, said Prof. Bjrn nfelt.

Key Points: 
  • Showing serial killing for AFM13- and AFM24-engaged NK cells in single cell resolution is impressive, said Prof. Bjrn nfelt.
  • Two additional posters (abstracts 880 and 881) present data on AFM24s ability to induce antibody dependent cellular phagocytosis (ADCP).
  • AFM13 is a first-in-class innate cell engager (ICE) that uniquely activates the innate immune system to destroy CD30-positive hematologic tumors.
  • The ROCK platform predictably generates customized innate cell engager (ICE) molecules, which use patients immune cells to destroy tumor cells.

Affimed Reports Third Quarter 2021 Financial Results and Highlights Operational Progress

Retrieved on: 
Wednesday, November 10, 2021

AFM24 monotherapy: Identified recommended Phase 2 dose (480 mg weekly); expansion cohorts to open during the fourth quarter of 2021.

Key Points: 
  • AFM24 monotherapy: Identified recommended Phase 2 dose (480 mg weekly); expansion cohorts to open during the fourth quarter of 2021.
  • HEIDELBERG, Germany, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the quarter ended September 30, 2021, and provided an update on clinical and corporate progress.
  • Affimed prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board.
  • Affimed will host a conference call and webcast today, November 10, 2021, at 8:30 a.m. EST to discuss third quarter 2021 financial results and recent corporate developments.

Heidelberg records half-year profit and high order backlog

Retrieved on: 
Wednesday, November 10, 2021
Saskatchewan River Sturgeon Management Board, China Printing Museum, Industry, Tax, Retirement, Investor relations, Pension, Technology, Growth, World Creativity and Innovation Day, Heidelberg, EBITDA, Sale, Partnership, Twitter, EBIT, Solution, Heidelberger Druckmaschinen, Motor vehicle, Group, CFO, Cryptocurrency

"The highly positive developments in our growth areas and our improved cost-efficiency underline that Heidelberg is doing very well.

Key Points: 
  • "The highly positive developments in our growth areas and our improved cost-efficiency underline that Heidelberg is doing very well.
  • Heidelberg is benefiting from continued high growth in its largest single marketChinapartly due to the company's well-established local production operations.
  • In packaging printing, too, Heidelberg has seen high demand during the half-year, with incoming orders up over 36percent on the previous year.
  • After taxes, Heidelberg recorded a profit of 13million, following a figure of -9million in the previous year.